Bloomage Biotechnology Corp Ltd (688363) - Total Assets
Based on the latest financial reports, Bloomage Biotechnology Corp Ltd (688363) holds total assets worth CN¥8.47 Billion CNY (≈ $1.24 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688363 net assets for net asset value and shareholders' equity analysis.
Bloomage Biotechnology Corp Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Bloomage Biotechnology Corp Ltd's total assets have evolved over time, based on quarterly financial data.
Bloomage Biotechnology Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bloomage Biotechnology Corp Ltd's total assets of CN¥8.47 Billion consist of 31.7% current assets and 68.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.3% |
| Accounts Receivable | CN¥592.65 Million | 6.9% |
| Inventory | CN¥1.25 Billion | 14.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥490.63 Million | 5.7% |
| Goodwill | CN¥174.09 Million | 2.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Bloomage Biotechnology Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Bloomage Biotechnology Corp Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bloomage Biotechnology Corp Ltd's current assets represent 31.7% of total assets in 2024, a decrease from 54.7% in 2012.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 25.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 14.4% of total assets.
Bloomage Biotechnology Corp Ltd Competitors by Total Assets
Key competitors of Bloomage Biotechnology Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €13.95 Billion |
|
Luxi Chemical Group Co Ltd
SHE:000830
|
China | CN¥35.95 Billion |
|
Dyno Nobel Ltd
AU:DNL
|
Australia | AU$7.83 Billion |
|
Fujian Kuncai Material Tech
SHG:603826
|
China | CN¥4.98 Billion |
|
Lianhe Chemical Technology Co Ltd
SHE:002250
|
China | CN¥13.79 Billion |
|
Sichuan Tianqi Lithium Industries Inc
SHE:002466
|
China | CN¥73.96 Billion |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
China | CN¥2.56 Billion |
|
Asia Cuanon Tech (Shanghai)
SHG:603378
|
China | CN¥5.38 Billion |
Bloomage Biotechnology Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.50 | 2.36 | 6.41 |
| Quick Ratio | 1.42 | 1.20 | 5.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.56 Billion | CN¥1.55 Billion | CN¥3.09 Billion |
Bloomage Biotechnology Corp Ltd - Advanced Valuation Insights
This section examines the relationship between Bloomage Biotechnology Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.78 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 2.2% |
| Total Assets | CN¥8.66 Billion |
| Market Capitalization | $2.91 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bloomage Biotechnology Corp Ltd's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bloomage Biotechnology Corp Ltd's assets grew by 2.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bloomage Biotechnology Corp Ltd (2012–2024)
The table below shows the annual total assets of Bloomage Biotechnology Corp Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.66 Billion ≈ $1.27 Billion |
+2.20% |
| 2023-12-31 | CN¥8.47 Billion ≈ $1.24 Billion |
-2.44% |
| 2022-12-31 | CN¥8.68 Billion ≈ $1.27 Billion |
+15.70% |
| 2021-12-31 | CN¥7.50 Billion ≈ $1.10 Billion |
+31.26% |
| 2020-12-31 | CN¥5.72 Billion ≈ $836.56 Million |
+14.99% |
| 2019-12-31 | CN¥4.97 Billion ≈ $727.51 Million |
+140.06% |
| 2018-12-31 | CN¥2.07 Billion ≈ $303.05 Million |
+9.98% |
| 2017-12-31 | CN¥1.88 Billion ≈ $275.55 Million |
+11.81% |
| 2016-12-31 | CN¥1.68 Billion ≈ $246.45 Million |
-23.42% |
| 2015-12-31 | CN¥2.20 Billion ≈ $321.81 Million |
+127.79% |
| 2014-12-31 | CN¥965.44 Million ≈ $141.27 Million |
+25.66% |
| 2013-12-31 | CN¥768.31 Million ≈ $112.43 Million |
+62.00% |
| 2012-12-31 | CN¥474.26 Million ≈ $69.40 Million |
-- |
About Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature nam… Read more